InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,003.15
(
0.32%
)
US TECH 100
20,498.80
(
-0.09%
)
Dow Jones
44,123.88
(
0.48%
)
Brent Oil
72.07
(
0.62%
)
Bitcoin
92,746.64
(
5.49%
)
Post# of 253590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

donotknowityet

Send PM Follow Ignore
Followers 0
Posts 102
Boards Moderated 0
Alias Born 06/30/2005

donotknowityet

Re: rfj1862 post# 39863

Tuesday, 12/26/2006 11:04:53 AM

Tuesday, December 26, 2006 11:04:53 AM

Post# of 253590
John, RPRX's proellex competes with AEZS's Cetrorelix, that completed a seven Phase II program in endometriosis.

What is your take on it?

Pump: I am long in AEZS. It has a huge pipeline that comes pretty much free, as its approved medications, cash, its share of Atrium (ATB.TO itself a very undervalued nutritional company about to be distributed to shareholders) and royalty revenues from already approved drugs essentially cover the current share price.

Dunno
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up